ASCO 2021: LAG-3 is now a validated target in Melanoma,

In the Checkmate-067 study, Yervoy + Opdivo showed a PFS of 11.5 months … can be key for clinical adoption, but they are still skeptical of its efficacy., In the Checkmate-067 study, Yervoy + Opdivo showed a PFS of 11.5 months … can be key for clinical adoption, but they are still skeptical of its efficacy., Read More

Scroll to Top